Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Fineline Cube Dec 30, 2025
Company Medical Device

Venus Medtech’s VenusP-Valve Used Again in US Compassionate Case

Fineline Cube Aug 16, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the second US market compassionate use of its...

Drug

Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review

Fineline Cube Aug 16, 2022

China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m

Fineline Cube Aug 16, 2022

US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...

Company Drug

CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti

Fineline Cube Aug 16, 2022

The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...

Company Drug

Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review

Fineline Cube Aug 16, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...

Company Drug

Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC

Fineline Cube Aug 16, 2022

China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...

Company Drug

Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Aug 15, 2022

Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...

Company

EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs

Fineline Cube Aug 15, 2022

US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...

Company

Novartis Aims for China to Be Second – Largest Market by 2024

Fineline Cube Aug 15, 2022

Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...

Company Deals R&D

ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition

Fineline Cube Aug 15, 2022

Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first...

Company Deals Digital

ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China

Fineline Cube Aug 15, 2022

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with...

Company Deals

E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products

Fineline Cube Aug 15, 2022

E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed...

Company Deals Digital Hospital

KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions

Fineline Cube Aug 15, 2022

Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a...

Company Drug

Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China

Fineline Cube Aug 15, 2022

China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...

Company Deals

Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development

Fineline Cube Aug 15, 2022

Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an...

Company Drug

Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study

Fineline Cube Aug 15, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Company Drug

Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer

Fineline Cube Aug 15, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...

Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Fineline Cube Aug 12, 2022

Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...

Posts pagination

1 … 573 574 575 … 602

Recent updates

  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.